Trial record 1 of 1 for:    Atrial Fibrillation Follow-up Investigation of Rhythm Management
Previous Study | Return to List | Next Study

Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM)

This study has been completed.
Sponsor:
Information provided by:
National Heart, Lung, and Blood Institute (NHLBI)
ClinicalTrials.gov Identifier:
NCT00000556
First received: October 27, 1999
Last updated: March 24, 2016
Last verified: November 2005
  Purpose
To compare two standard treatment strategies for atrial fibrillation: ventricular rate control and anticoagulation vs. rhythm control and anticoagulation.

Condition Intervention Phase
Arrhythmia
Atrial Fibrillation
Cardiovascular Diseases
Heart Diseases
Drug: amiodarone
Drug: sotalol
Drug: propafenone
Drug: flecainide
Drug: quinidine
Drug: moricizine
Drug: disopyramide
Drug: procainamide
Drug: adrenergic beta antagonists
Drug: verapamil
Drug: diltiazem
Drug: digoxin
Procedure: catheter ablation
Device: pacemaker, artificial
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Primary Purpose: Treatment

Resource links provided by NLM:


Further study details as provided by National Heart, Lung, and Blood Institute (NHLBI):

Study Start Date: March 1995
Estimated Study Completion Date: September 2002
  Show Detailed Description

  Eligibility

Ages Eligible for Study:   65 Years to 100 Years   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria
Elderly men and women with atrial fibrillation and other risk factors for stroke.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00000556

Sponsors and Collaborators
National Heart, Lung, and Blood Institute (NHLBI)
Investigators
OverallOfficial: H. Greene Statistics and Epidemiology Research Corporation (S.E.R.C.)
  More Information

Publications:

Study Data/Documents: Individual Participant Data Set  This link exits the ClinicalTrials.gov site
Identifier: AFFIRM
NHLBI provides controlled access to IPD through BioLINCC. Access requires registration, evidence of local IRB approval or certification of exemption from IRB review, and completion of a data use agreement.

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
ClinicalTrials.gov Identifier: NCT00000556     History of Changes
Other Study ID Numbers: 100 
Study First Received: October 27, 1999
Last Updated: March 24, 2016
Health Authority: United States: Federal Government

Additional relevant MeSH terms:
Atrial Fibrillation
Cardiovascular Diseases
Heart Diseases
Arrhythmias, Cardiac
Pathologic Processes
Digoxin
Verapamil
Amiodarone
Flecainide
Quinidine
Procainamide
Sotalol
Propafenone
Disopyramide
Moricizine
Adrenergic Agents
Diltiazem
Adrenergic beta-Antagonists
Anti-Arrhythmia Agents
Cardiotonic Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Protective Agents
Physiological Effects of Drugs
Neurotransmitter Agents
Calcium Channel Blockers
Membrane Transport Modulators
Vasodilator Agents
Potassium Channel Blockers
Sodium Channel Blockers

ClinicalTrials.gov processed this record on August 25, 2016